Alcaligenes Lipid A Functions as a Superior Mucosal Adjuvant to Monophosphoryl Lipid A via the Recruitment and Activation of CD11b+ Dendritic Cells in Nasal Tissue.

Alcaligenes MPLA chemokines lipid A nasal vaccine stromal cells

Journal

International immunology
ISSN: 1460-2377
Titre abrégé: Int Immunol
Pays: England
ID NLM: 8916182

Informations de publication

Date de publication:
25 Nov 2023
Historique:
received: 18 06 2023
medline: 26 11 2023
pubmed: 26 11 2023
entrez: 25 11 2023
Statut: aheadofprint

Résumé

We previously demonstrated that Alcaligenes-derived lipid A (ALA), which is produced from an intestinal lymphoid tissue-resident commensal bacterium, is an effective adjuvant for inducing antigen-specific immune responses. To understand the immunologic characteristics of ALA as a vaccine adjuvant, we here compared the adjuvant activity of ALA with that of a licensed adjuvant (monophosphoryl lipid A, MPLA) in mice. Although the adjuvant activity of ALA was only slightly greater than that of MPLA for subcutaneous immunization, ALA induced significantly greater IgA antibody production than MPLA during nasal immunization. Regarding the underlying mechanism, ALA increased and activated CD11b+ CD103- CD11c+ dendritic cells in the nasal tissue by stimulating chemokine responses. These findings revealed the superiority of ALA as a mucosal adjuvant due to the unique immunologic functions of ALA in nasal tissue.

Identifiants

DOI: 10.1093/intimm/dxad045 PMID: 38006376
pubmed: 38006376
pii: 7451066
doi: 10.1093/intimm/dxad045
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Society for Immunology.

Auteurs

Xiao Sun (X)

Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Koji Hosomi (K)

Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan.

Atsushi Shimoyama (A)

Graduate School of Science, Osaka University, Osaka, 560-0043, Japan.
Collaborative Research between NIBIOHN and Graduate School of Science, Forefront Research Center, Osaka University, Osaka, 560-0043, Japan.

Ken Yoshii (K)

Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan.
Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan.

Azusa Saika (A)

Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan.

Haruki Yamaura (H)

Graduate School of Science, Osaka University, Osaka, 560-0043, Japan.

Takahiro Nagatake (T)

Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan.
Laboratory of Functional Anatomy, Department of Life Sciences, School of Agriculture, Meiji University, Kanagawa, 214-8571, Japan.

Hiroshi Kiyono (H)

Division of Gastroenterology, Department of Medicine, University of California-San Diego (UCSD), San Diego, CA, 92093, United States.
Chiba University (CU)-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UCSD, San Diego, CA, 92093, United States.
Future Medicine Education and Research Organization, Chiba University, Chiba, 260-8670, Japan.
Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, 260-8677, Japan.

Koichi Fukase (K)

Graduate School of Science, Osaka University, Osaka, 560-0043, Japan.
Collaborative Research between NIBIOHN and Graduate School of Science, Forefront Research Center, Osaka University, Osaka, 560-0043, Japan.

Jun Kunisawa (J)

Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, 567-0085, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.
Graduate School of Science, Osaka University, Osaka, 560-0043, Japan.
Collaborative Research between NIBIOHN and Graduate School of Science, Forefront Research Center, Osaka University, Osaka, 560-0043, Japan.
Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan.
International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Research Organization for Nano and Life Innovation, Waseda University, Tokyo, 162-0041, Japan.
Graduate School of Dentistry, Osaka University, Suita, 565-0871, Japan.

Classifications MeSH